Quispe, Renato’s team published research in Current Atherosclerosis Reports in 24 | CAS: 6217-54-5

Current Atherosclerosis Reports published new progress about 6217-54-5. 6217-54-5 belongs to catalysis-chemistry, auxiliary class Alkenyl,Carboxylic acid,Aliphatic hydrocarbon chain,Metabolic Enzyme,RAR/RXR,Natural product, name is Docosahexaenoic Acid, and the molecular formula is C22H32O2, Related Products of catalysis-chemistry.

Quispe, Renato published the artcileControversies in the Use of Omega-3 Fatty Acids to Prevent Atherosclerosis, Related Products of catalysis-chemistry, the publication is Current Atherosclerosis Reports (2022), 24(7), 571-581, database is CAplus and MEDLINE.

A review. Abstract: Purpose of Review: We discuss current controversies in the clin. use of omega-3 fatty acids (FA), primarily eicosapentaenoic acid (EPA) and docosahexaenoic acid (DHA), and examine discrepancies between recent trials. Furthermore, we discuss potential side effects reported in these studies and the role of mixed omega-3 FA dietary supplements and concerns about their use. Recent Findings: REDUCE-IT showed that addition of icosapent Et, a highly purified form of EPA, can reduce risk of cardiovascular events among statin-treated individuals with high triglycerides. Addnl. supportive evidence for EPA has come from other trials and meta-analyses of omega-3 FA therapy. In contrast, trials of mixed EPA/DHA products have consistently failed to improve cardiovascular outcomes. Discrepancies in results reported in RCTs could be explained by differences in omega-3 FA products, dosing, study populations, and study designs including the placebo control formulation. Evidence obtained from highly purified forms should not be extrapolated to other mixed formulations, including “over-the-counter” omega-3 supplements. Summary: Targeting TG-rich lipoproteins represents a new frontier for mitigating ASCVD risk. Clin. and basic research evidence suggests that the use of omega-3 FA, specifically EPA, appears to slow atherosclerosis by reducing triglyceride-rich lipoproteins and/or inflammation, therefore addressing residual risk of clin. ASCVD.

Current Atherosclerosis Reports published new progress about 6217-54-5. 6217-54-5 belongs to catalysis-chemistry, auxiliary class Alkenyl,Carboxylic acid,Aliphatic hydrocarbon chain,Metabolic Enzyme,RAR/RXR,Natural product, name is Docosahexaenoic Acid, and the molecular formula is C22H32O2, Related Products of catalysis-chemistry.

Referemce:
https://courses.lumenlearning.com/boundless-chemistry/chapter/catalysis/,
Catalysis – Wikipedia